Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ERBB2

ERBB2

Basics

Aliases:
This biomarker is also known as:
  • Receptor tyrosine-protein kinase erbB-2,
  • p185erbB2,
  • Tyrosine kinase-type cell surface receptor HER2,
  • NEU,
  • Proto-oncogene c-ErbB-2,
  • Metastatic lymph node gene 19 protein,
  • HER-2/neu,
  • HER-2,
  • MLN19,
  • CD340,
  • TKR1,
  • MLN 19,
  • CD_antigen=CD340,
  • NGL,
  • v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian),
  • Proto-oncogene Neu,
  • HER2,
  • v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog),
  • c-ErbB-2,

View in BioMuta

Description…

ERBB2, often known as HER-2/neu, a single-pass type I membrane protein, is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It is part of several cell surface receptor complexes. ERBB2 has no ligand binding domain of its own, and needs a coreceptor for ligand binding. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele Ile654/Ile655. There are several transcript variants resulting from alternative splicing events. Some isoforms have not been fully characterized yet.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

Performance Comment

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

Amplification and/or overexpression of the ERBB2 gene has been reported in numerous cancers, including breast and ovarian tumors. Studies have suggested that ERBB2 overexpression represented a major negative prognostic indicator for patients with several human cancers, including endometrial carcinomas

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html